Market›Health Care›Pharmaceuticals›Pharmaceuticals
IPSEN S A ADR

IPSEY

$48.01Apr 26, 2021 – Apr 24, 2026
Health CarePharmaceuticals$16.00B
MVM
+$16.00B
TD Variance
0.038

Every news event mapped to its market reaction — 48 events, 61 months of data. No predictions, just what happened.

PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2026-02-12+12.6%newsSeeking AlphaGenfit adds $20M as Ipsen records strong sales for liver drug
2026-02-12+12.6%earningsSeeking AlphaIpsen S.A. (IPSEY) Q4 2025 Earnings Call Transcript
2026-02-12+12.6%earningsSeeking AlphaIpsen S.A. 2025 Q4 - Results - Earnings Call Presentation
2026-02-12+12.6%earningsSeeking AlphaIpsen S.A. Non-GAAP EPS of 12.09, revenue of 3.68B; sets full-year 2026 guidance and mid-term outlook
2025-02-13-8.5%earningsSeeking AlphaIpsen S.A. 2024 Q4 - Results - Earnings Call Presentation
2025-02-13-8.5%expansionSeeking AlphaIpsen targets 5%+ sales growth and 30%+ margin for 2025 amid strong pipeline and launches
2025-02-13-8.5%earningsSeeking AlphaIpsen S.A. (IPSEY) Q4 2024 Earnings Call Transcript
2025-02-13-8.5%earningsSeeking AlphaIpsen S.A. Non-GAAP EPS of 10.27, revenue of 3.4B; initiates FY25 outlook
2025-04-16-6.9%earningsSeeking AlphaIpsen S.A. (IPSEY) Q1 2025 Earnings Call Transcript
2024-07-25-6.4%earningsSeeking AlphaIpsen S.A. Non-GAAP EPS of 4.78, revenue of 1.66B; raises FY24 outlook
2025-10-22+6.2%earningsSeeking AlphaIpsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript
2025-10-22+6.2%earningsSeeking AlphaIpsen S.A. 2025 Q3 - Results - Earnings Call Presentation
2025-10-22+6.2%earningsSeeking AlphaIpsen S.A. reports Q3 results; upgrades FY outlook
2026-01-14+4.3%newsSeeking AlphaIpsen S.A. (IPSEY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-14+4.3%legalSeeking AlphaIpsen rises on FDA breakthrough therapy status for blood cancer therapy
2026-04-01+4.0%newsGlobeNewswireIpsen announces the availability of its 2025 Universal Registration Document
2025-04-30+3.9%newsIpsenFormalities for making available and consulting preparatory documents to the 2025 Annual General Meeting - Ipsen
2024-06-10-3.6%newsSeeking AlphaIpsen gains accelerated approval for elafibranor for rare liver disease
2024-07-05-3.1%newsSeeking AlphaHutchmed gains as Ipsen-partnered lymphoma drug undergoes review in China
2025-06-20-2.8%newsSeeking AlphaMadrigal, Ipsen, SpringWorks get EU backing for their drugs
2026-04-22-1.7%newsGlobeNewswireIpsen S.A. - Information relating to the holding of the Combined Shareholders’ Meeting of 13 May 2026
2026-04-22-1.7%executiveGlobeNewswireElkedonia strengthens Board of Directors with appointment of Pierre d’Epenoux as Independent Chairman
2026-04-22-1.7%newsGlobeNewswireOjemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
2024-04-24+1.7%earningsSeeking AlphaIpsen S.A. reports Q1 results; reaffirms full-year guidance
2025-12-01-1.6%newsIpsenIpsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 - Ipsen
2026-04-23-1.5%earningsGlobeNewswireIpsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
2026-04-23-1.5%earningsSeeking AlphaIpsen S.A. (IPSEY) Q1 2026 Earnings Call Transcript
2026-04-23-1.5%earningsSeeking AlphaIpsen S.A. 2026 Q1 - Results - Earnings Call Presentation
2026-04-23-1.5%earningsSeeking AlphaIpsen S.A. reports Q1 results; reaffirms FY outlook
2024-07-26-1.4%newsSeeking AlphaIpsen liver disease drugs endorsed in EU
2022-06-27+1.4%M&AIpsenIpsen to Acquire Epizyme - Growth in Oncology | Ipsen Global - Ipsen
2024-04-05-0.9%M&ASeeking AlphaIpsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors (IPSEY) - Seeking Alpha
2024-10-23+0.8%earningsSeeking AlphaIpsen S.A. reports Q3 results; raises FY24 guidance
2022-08-05+0.8%newsIpsenIpsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022 - Ipsen
2025-08-21+0.8%earningsSeeking AlphaIpsen S.A. 2025 Q2 - Results - Earnings Call Presentation
2024-07-02+0.6%expansionSeeking AlphaIpsen expands collaboration agreement with Exelixis
2026-04-04-0.5%newsSimply Wall St.Is It Time To Reassess Ipsen (ENXTPA:IPN) After Its 65% One-Year Share Price Jump
2026-04-03-0.5%newsGlobeNewswireIpsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer
2025-07-24-0.4%newsSeeking AlphaIpsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors
2024-06-07-0.4%expansionSeeking AlphaIpsen and Marengo Therapeutics announce second strategic partnership
2023-06-01-0.3%newsIpsenIpsen SA initiates a share buy-back program to cover its free employee share-allocation plan - Ipsen
2023-05-31-0.3%newsIpsenCombined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023 - Ipsen
2026-01-06-0.2%newsGlobeNewswireIpsen – Half year statement – 2025 12 31 - GlobeNewswire
2024-07-11+0.2%expansionSeeking AlphaIpsen, Foreseen enter exclusive global licensing agreement for antibody-drug conjugate
2025-08-01+0.1%earningsSeeking AlphaIpsen S.A. (IPSEY) Q2 2025 Earnings Call Transcript
2026-04-02+0.1%newsGlobeNewswireGENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
2026-04-02+0.1%executiveProactiveScancell CFO to step down as cancer immunotherapy developer names interim replacement
2026-04-24—newsSimply Wall St.Ipsen (ENXTPA:IPN) Valuation Check After Strong Recent Share Price Performance
tickerdossier.comtickerdossier.substack.com